{"entity":{"id":"idp-023","kind":"drug","name":"IDP-023","aka":["g-NK cells"],"tldr":"IDP-023 is an experimental allogeneic natural killer cell therapy from Indapta Therapeutics, in phase 2 trials for relapsed or refractory multiple myeloma and relapsed or refractory non-Hodgkin lymphoma.","summary":"IDP-023 (g-NK cells) is an allogeneic natural killer (NK) cell therapy from Indapta Therapeutics. Off-the-shelf NK cells from healthy donors, drawn from a subset deficient in the FceR1g protein (g-NK cells); given alone or with tumour-targeting antibodies. Its furthest stage is phase 2, for relapsed or refractory multiple myeloma and relapsed or refractory non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. NCT06119685 (phase 1/2, haematologic cancers) RECRUITING. The multiple sclerosis study NCT06677710 is SUSPENDED (non-oncology). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Indapta Therapeutics: indapta.com","url":"https://indapta.com/"},{"label":"Indapta Therapeutics: indapta.com","url":"https://indapta.com/"},{"label":"Indapta Therapeutics: indapta.com","url":"https://indapta.com/"},{"label":"Indapta Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06119685"},{"label":"ClinicalTrials.gov: trials of IDP-023","url":"https://clinicaltrials.gov/search?intr=IDP-023"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["indapta-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06119685"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"IDP-023","modality":"Allogeneic natural killer (NK) cell therapy","mechanism":"Off-the-shelf NK cells from healthy donors, drawn from a subset deficient in the FceR1g protein (g-NK cells); given alone or with tumour-targeting antibodies.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/idp-023/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"company":[{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/"}],"trial":[{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/"}]}}